EH
RXRX icon

Equitable Holdings’s Recursion Pharmaceuticals RXRX Stock Holding History

Equitable Holdings’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$40.9K – 1748
2025
Q4 		$40.9K Sell
10,000
-29,400
-75% -$146K ﹤0.01% 1565
2025
Q3 		$192K Buy
39,400
+2,600
+7% +$13.7K ﹤0.01% 1462
2025
Q2 		$186K Sell
36,800
-19,589
-35% -$96.2K ﹤0.01% 1386
2025
Q1 		$298K Buy
56,389
+37,235
+194% +$271K ﹤0.01% 1099
2024
Q4 		$129K Buy
+19,154
New +$129K ﹤0.01% 1222

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Equitable Holdings's RXRX Position: Q1 2026 in Review

Equitable Holdings sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 10,000 shares — an estimated $40.9K sold.

Equitable Holdings first reported a position in RXRX in Q4 2024 and held it in 5 quarters. The position peaked at $298K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Equitable Holdings reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Equitable Holdings sold 10,000 Recursion Pharmaceuticals shares in Q1 2026, an estimated $40.9K.
  • Equitable Holdings first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • Equitable Holdings's Recursion Pharmaceuticals position peaked at $298K in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Equitable Holdings's 13F filing for Q1 2026, filed 15 May 2026.